Treatment Information

Back

Melanoma treatment details. Immunotherapy.

University Hospital of Siena, Siena, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Siena
Treatments:ImmunotherapyHospital:University Hospital of Siena
Drugs:Journal:Link
Date:Oct 2013

Description:

Patients:
This study involved 74 pretreated advanced melanoma patients with a median age of 56 years, 62.2% of whom were male.

Treatment:
Patients were treated with the immune therapy agent ipilimumab, which is an antibody to the CTLA-4 protein and enhances the immune response against cancer cells.

Toxicities:
The most severe toxicities were grade 4 pancytopenia (decreased number of blood cells numbers). Grade 3 diarrhea and pain were also reported.

Results:
The median overall survival was 7.0 months.

Support:
This study was partially funded by Bristol Myers Squibb, makers of ipilimumab.

Correspondence: Dr. Michele Maio; email: [email protected]



Back